Publication Name	World Journal of Hepatology
Manuscript ID	22537
Country	France

Received	2015-09-02 08:43
Peer-Review Started	2015-09-05 14:27
To Make the First Decision	2015-10-08 16:40
Return for Revision	2015-10-16 18:08
Revised	2015-10-27 22:15
Second Decision	2015-12-17 18:42
Accepted by Journal Editor-in-Chief	2015-12-17 19:00
Accepted by Executive Editor-in-Chief	2016-01-04 17:11
Articles in Press	2016-01-04 17:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-01-11 08:43
Publish the Manuscript Online	2016-01-15 09:49

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Ribavirin: Past, present and future
Manuscript Source	Invited Manuscript
All Author List	Véronique Loustaud-Ratti, Marilyne Debette-Gratien, Jérémie Jacques, Sophie Alain, Pierre Marquet, Denis Sautereau, Annick Rousseau and Paul Carrier
Funding Agency and Grant Number
Corresponding Author	Véronique Loustaud-Ratti, Professor, Fédération Hépatologie, Service d’Hépato-gastroentérologie, CHU Limoges, 2 Avenue Martin Luther King, 87042 Limoges, France. veronique.loustaud-ratti@unilim.fr
Key Words	Ribavirin; Hepatitis C; Peginterferon; Direct acting antiviral agents
Core Tip	Ribavirin plays a crucial role when asso-ciated with peginterferon, preventing relapses and breakthroughs and doubling the support vector regre-ssion rate. Its antiviral effect is weak and ribavirin could enhance the response of interferon-stimulated genes in the combination. Ribavirin is still useful in the era of approved new direct acting antiviral agents (DAAs), in order to shorter treatment duration in genotype 1 or 4 cirrhotic patients, in all options available for genotype 3 cirrhotic patients, and as the only drug associated with sofosbuvir in genotype 2. Preliminary data with interferon-free second generation DAAs combinations without ribavirin suggest that future of the drug is jeopardized.
Publish Date	2016-01-15 09:49
Citation	Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130
URL	http://www.wjgnet.com/1948-5182/full/v8/i2/123.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i2.123

Full Article (PDF)	WJH-8-123.pdf
Full Article (Word)	WJH-8-123.doc
Manuscript File	22537-Review.doc
Answering Reviewers	22537-Answering reviewers.pdf
Audio Core Tip	22537-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	22537-Conflict-of-interest statement.pdf
Copyright License Agreement	22537-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	22537-Language certificate.pdf
Peer-review Report	22537-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	22537-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	22537-Scientific misconduct check.pdf
Scientific Editor Work List	22537-Scientific editor work list.pdf